WO2004073627A2 - Methode et compositions therapeutiques pour administration topique - Google Patents

Methode et compositions therapeutiques pour administration topique Download PDF

Info

Publication number
WO2004073627A2
WO2004073627A2 PCT/US2004/004393 US2004004393W WO2004073627A2 WO 2004073627 A2 WO2004073627 A2 WO 2004073627A2 US 2004004393 W US2004004393 W US 2004004393W WO 2004073627 A2 WO2004073627 A2 WO 2004073627A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
nominal flux
photoageing
drug substance
flux
Prior art date
Application number
PCT/US2004/004393
Other languages
English (en)
Other versions
WO2004073627A3 (fr
Inventor
Adrian Francis Davis
Lionel Trottet
Tadataka Yamada
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to EP04711191A priority Critical patent/EP1594496A4/fr
Priority to JP2006503589A priority patent/JP2007525420A/ja
Priority to US10/545,772 priority patent/US20060142356A1/en
Publication of WO2004073627A2 publication Critical patent/WO2004073627A2/fr
Publication of WO2004073627A3 publication Critical patent/WO2004073627A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne une composition pharmaceutique pour administration topique sur la peau, renfermant du farglitazar, ou un sel acceptable au plan pharmaceutique de cette substance, et un excipient physiologiquement acceptable, ainsi que son emploi pour le traitement de maladies de la peau.
PCT/US2004/004393 2003-02-17 2004-02-13 Methode et compositions therapeutiques pour administration topique WO2004073627A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04711191A EP1594496A4 (fr) 2003-02-17 2004-02-13 Methode et compositions therapeutiques pour administration topique
JP2006503589A JP2007525420A (ja) 2003-02-17 2004-02-13 新規な治療方法および局所投与用組成物
US10/545,772 US20060142356A1 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0303600.1 2003-02-17
GBGB0303600.1A GB0303600D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions

Publications (2)

Publication Number Publication Date
WO2004073627A2 true WO2004073627A2 (fr) 2004-09-02
WO2004073627A3 WO2004073627A3 (fr) 2004-11-18

Family

ID=9953155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004393 WO2004073627A2 (fr) 2003-02-17 2004-02-13 Methode et compositions therapeutiques pour administration topique

Country Status (4)

Country Link
EP (1) EP1594496A4 (fr)
JP (1) JP2007525420A (fr)
GB (1) GB0303600D0 (fr)
WO (1) WO2004073627A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093747A2 (fr) * 2006-02-17 2007-08-23 Galderma Research & Development Utilisation du tesaglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
JP2008540621A (ja) * 2005-05-16 2008-11-20 ラボラトワール イネオフ グリセリド類を用いる角質性乾燥の処置
WO2010084066A1 (fr) * 2009-01-23 2010-07-29 F. Hoffmann-La Roche Ag Composition pharmaceutique comprenant de l'aleglitazar

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101965514A (zh) * 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
WO2002013812A1 (fr) * 2000-08-17 2002-02-21 Pershadsingh Harrihar A Traitements de maladies inflammatoires
US6573287B2 (en) * 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
DE60216453T2 (de) * 2001-06-20 2007-09-20 Merck Santé Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1594496A4 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540621A (ja) * 2005-05-16 2008-11-20 ラボラトワール イネオフ グリセリド類を用いる角質性乾燥の処置
WO2007093747A2 (fr) * 2006-02-17 2007-08-23 Galderma Research & Development Utilisation du tesaglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
FR2897534A1 (fr) * 2006-02-17 2007-08-24 Galderma Res & Dev Utilisation du tesaglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
WO2007093747A3 (fr) * 2006-02-17 2008-01-17 Galderma Res & Dev Utilisation du tesaglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
WO2010084066A1 (fr) * 2009-01-23 2010-07-29 F. Hoffmann-La Roche Ag Composition pharmaceutique comprenant de l'aleglitazar
CN102292074A (zh) * 2009-01-23 2011-12-21 霍夫曼-拉罗奇有限公司 包含阿格列扎的药物组合物
CN102292074B (zh) * 2009-01-23 2013-08-21 霍夫曼-拉罗奇有限公司 包含阿格列扎的药物组合物

Also Published As

Publication number Publication date
WO2004073627A3 (fr) 2004-11-18
EP1594496A4 (fr) 2006-05-03
GB0303600D0 (en) 2003-03-19
JP2007525420A (ja) 2007-09-06
EP1594496A2 (fr) 2005-11-16

Similar Documents

Publication Publication Date Title
Tanaji Emulgel: A comprehensive review for topical delivery of hydrophobic drugs
EP1594959A2 (fr) Methode therapeutique et compositions destinees a une administration topique
US11026934B2 (en) Topical retinoid compositions
JP5570992B2 (ja) 皮膚病又は皮膚病変の治療方法及び組成物
US10869822B2 (en) Compositions for treatment of dermatological diseases and conditions and methods of use thereof
JP2023022177A (ja) 治療用アプレミラスト局所組成物
KR20010012244A (ko) 활성형 비타민 ｄ3 유제성 로션제
US20060159648A1 (en) Novel therapeutic method and compositions for topical administration
US20110281947A1 (en) Methods of administering diclofenac compositions for treating photodamaged skin
Foster et al. Tazarotene.
KR20110019571A (ko) 헥사미딘류 및 레티노이드류를 함유하는 피부 개선 조성물
JP5891651B2 (ja) 角層細胞分化正常化用皮膚外用剤
US20100056644A1 (en) Pharmaceutical compositions containing anhydrous calcipotriene
RU2655305C2 (ru) Содержащие ретиноид фармацевтические композиции для местного применения типа эмульсии "масло в воде"
WO2004073627A2 (fr) Methode et compositions therapeutiques pour administration topique
US20130165526A1 (en) Topical treatment with dapsone in g6pd-deficient patients
US20120252863A1 (en) Triptans for the treatment of psoriasis
US20060142356A1 (en) Novel therapeutic method and compositions for topical administration
JPH08109128A (ja) アレルギー性皮膚疾患治療用外用剤
WO2017109761A1 (fr) Composition topique pour le traitement de l'acné
US10722503B2 (en) Glitazones for topical application
Chadha Design, Optimization and Evaluation of a Novel Emulgel of Ibuprofen for Enhanced Skin Delivery using Formulating for Efficacy™ software
EP1686975A1 (fr) UTILISATION DU FEPRADINOL POUR LA PREPARATION D’UNE COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE LA ROSACEE
MX2007006059A (es) Composicion de crema desmanchadora de piel.
CA2782048A1 (fr) Utilisation d'un compose dipyridyl pour traiter la rosacee

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004711191

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006503589

Country of ref document: JP

ENP Entry into the national phase in:

Ref document number: 2006142356

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10545772

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004711191

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10545772

Country of ref document: US